Home > Insider Trading > Filing (0001225208-23-005754)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1099800	Edwards Lifesciences Corp	EW	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	364316614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1204551	A Michael Mussallem	One Edwards Way Irvine CA 92614	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-07	20,777	$0.00	81,725	No	4	M	Direct
Common Stock	Acquisiton	2023-05-10	29,375	$35.20	111,100	No	4	M	Direct
Common Stock	Disposition	2023-05-10	5,984	$88.94	105,116	No	4	S	Direct
Common Stock	Disposition	2023-05-10	9,500	$0.00	95,616	No	4	G	Direct
Common Stock	Disposition	2023-05-10	13,891	$88.29	81,725	No	4	S	Direct
Common Stock	Acquisiton	2023-05-10	9,500	$0.00	3,616,922	No	4	G	Indirect	By Living Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	G	Direct
No	4	S	Direct
No	4	G	Indirect	By Living Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Rights	Disposition	2023-05-07	20,777	$0.00	20,777	$0.00
Common Stock	Employee Stock Option (Right to Acquire)	Disposition	2023-05-10	29,375	$0.00	29,375	$35.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,698	2023-05-07	2027-05-06	No	4	M	Direct
0	2016-06-12	2023-05-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	371,690	Indirect	401(k)

Footnotes

On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022.
This transaction was executed in multiple trades at prices ranging from $88.84 to $89.25 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $87.83 to $88.83 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.